News & Updates

Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).

Treatment with methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, does not significantly reduce the severity of acute pancreatitis (AP) relative to placebo, a study has shown.

Older-generation generic antiobesity medications (AOMs) for weight maintenance may be prescribed to patients who have achieved successful weight loss with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, suggests a study.

Data presented at APSR 2024 demonstrate the ability of glucagon-like peptide 1 receptor agonists (GLP1-RAs) to benefit obese individuals with asthma.

Primary treatment with either selective laser trabeculoplasty (SLT) or prostaglandin analog (PGA) drops for ocular hypertension and open-angle glaucoma results in a decrease in intraocular pressure (IOP), and this benefit is greater with higher baseline IOP, a study has shown.

Use of metformin in nondiabetic breast cancer patients improves their clinical and pathological response to neoadjuvant AC-T chemotherapy, reveals a recent study.